JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Literature - Publication Review
Targeting BMPR2 signaling in pulmonary arterial hypertension with wild-type and non-osteogenic BMP9 variants
This publication review examines research on wild-type BMP9 and a non-osteogenic BMP9 variant (A347E) as approaches to modulate BMPR2 signaling in pulmonary arterial hypertension (PAH), using AlphaLISA™ SureFire® Ultra™ assays to assess SMAD pathway activation.
Read the publication review to explore:
- An overview of BMPR2 signaling in pulmonary arterial hypertension (PAH) and the potential of BMP9-based approaches to modulate this pathway.
- In vitro and in vivo characterization of wild-type BMP9 and the non-osteogenic A347E variant, including assessment of SMAD1/3 signaling and target gene activation
- How AlphaLISA SureFire® Ultra assays support the characterization of SMAD signaling in response to wild-type BMP9 and the A347E variant.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Targeting BMPR2 signaling in pulmonary arterial hypertension with wild-type and non-osteogenic BMP9 variants
